Oragenics, Inc. (NYSEAMERICAN:OGEN – Get Rating) crossed above its two hundred day moving average during trading on Tuesday . The stock has a two hundred day moving average of $2.25 and traded as high as $3.17. Oragenics shares last traded at $3.15, with a volume of 9,443 shares traded.
Wall Street Analyst Weigh In
Separately, StockNews.com assumed coverage on Oragenics in a research note on Tuesday, April 25th. They issued a “sell” rating for the company.
Oragenics Stock Up 0.5 %
The stock has a market cap of $6.16 million, a P/E ratio of -24.21 and a beta of 0.19. The company has a 50-day simple moving average of $3.56 and a two-hundred day simple moving average of $2.25.
Institutional Investors Weigh In On Oragenics
Oragenics Company Profile
Oragenics, Inc develops antibiotics for infectious diseases in the United States. The company engages in the development and commercialization of NT-CoV2-1, an intranasal vaccine candidate that provides immunity from the novel severe acute respiratory syndrome coronavirus; and Terra CoV-2, an intramuscular vaccine candidate that provides immunity from the novel severe acute respiratory syndrome coronavirus.
- Get a free copy of the StockNews.com research report on Oragenics (OGEN)
- Airline ETFs: What They Are and How to Invest
- Williams-Sonoma Is The Retail Value Play, Here’s Why
- Ladder Corporation: Climbing Higher And Paying 9% Yield
- Microbot Medical spikes 150% on its Endovascular Surgical Robot
- PetMed Express: Charts Say This Could Be The Bottom
Receive News & Ratings for Oragenics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Oragenics and related companies with MarketBeat.com's FREE daily email newsletter.